Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 12, 2026

I’m 66, have a paid-off house and $100K sitting in cash. Would this be a good time to invest it all in the S&P 500?

View original at finance.yahoo.com
“She also has about $100,000 in cash sitting in a high-yield savings account”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The stock market isn't pricing current events but rather what the world will look like six to 12 months from now

    60% confidence
  • There are concerns that the S&P 500 stock market rally cannot last forever

    60% confidence
  • Investors are betting the Iran conflict will be short-lived and that China can push Tehran toward de-escalation following the Trump-Xi meeting

    60% confidence
  • The S&P 500 is 16.5% above this year's low

    60% confidence
  • A specific unidentified asset will surge 400% in a year; investors should not miss this 'explosion'

    60% confidence
  • The blockade of the Strait of Hormuz has led to the largest oil-supply disruption in history

    60% confidence
  • Nearly 50% of Americans are making one big Social Security mistake that should be fixed immediately

    60% confidence
  • S&P 500 gains have been driven in part by high demand for new data centers to fuel the rapid growth of AI, despite inflation concerns from rising oil prices

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com